VTRS
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Viatris Inc (VTRS) until May 8, 2026. Viatris Inc reported in an 8-K filed May 4, 2026 that Doretta Mistras resigned as Chief Financial Officer, effective May 8, 2026. The proxy statement of Viatris Inc reports total compensation of $6,373,692 for Doretta Mistras in fiscal 2024, including a base salary of $809,135. Doretta Mistras has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Viatris Inc on March 19, 2026. The companies whose calls Doretta Mistras spoke on are classified in the Healthcare sector.
“On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity. Ms. Mistras will cease to serve as Chief Financial Officer effective May 8, 2026 and will remain employed by the Company until May 22, 2026 for transition purposes.”
“Good morning and welcome again to everyone that's here in the room and for those that are listening in. I am Doretta Mistris, the CFO of Vietris.”
“My remarks today will focus on the key highlights from our fourth quarter and full year 2025 25 results, and our growth outlook for 2026, which we believe will be powered by continued commercial momentum and the anticipated benefits from our strategic review.”
“I am pleased to report that we had another strong quarter, underscoring the continued performance of our broad global portfolio of generics and brands.”
“Today I will walk you through the key drivers and takeaways for the quarter, the progress we're making against our capital allocation plan, and our outlook for the remainder of the year.”
“Building on Scott's earlier comments, this has been an exceptionally strong quarter, and our first full quarter on an ex-divestiture basis, the results of which are highly encouraging and indicative of the strong momentum we anticipate carrying into the new year.”
Start not stated–2026-05-08
VTRS
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Viatris Inc (VTRS) | Chief Financial Officer | $809,135 | $6,373,692 |